Inclusion Criteria:

• Evidence of a personally signed and dated informed consent form (ICF) indicating that the participant has been informed of all pertinent aspects of the study.
• Willing and able to comply with scheduled visits, investigational plan, pregnancy test, and other procedures.
• Expected to be available for the duration of the study and can be contacted by telephone during study participation.
• Females aged ≥ 45 (with roughly 80% of enrolled participants over the age of 50).
• Presence of uterus.
• Abnormal uterine bleeding requiring medical attention, including but not limited to:
  • abnormal uterine bleeding
  • postmenopausal bleeding
  • suspected endometrial hyperplasia
  • other clinical suspicion of endometrial cancers including uterine sarcomas
  • benign conditions including vaginal prolapse, fibroids, ovarian cysts, or irregular bleeding not responsive to conservative treatment.

Exclusion Criteria:

• Investigator site staff members directly involved in the conduct of the study and their family members or participants who are PinkDx, Inc. employees or their family members.
• Other acute or chronic medical or psychiatric conditions that would increase the risk associated with study participation in the judgment of the Investigator.
• Women who have undergone a hysterectomy.
• Women with a known history of endometrial cancer or uterine sarcoma.
• Women who have received prior treatment for endometrial cancer.
• Inability or unwillingness to sign informed consent.
• Pregnancy.
• Women who have used a tampon within 7 days of sample collection.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/29/2024. Questions regarding updates should be directed to the study team contact.